33rd week of 2010 patent applcation highlights part 19 |
Patent application number | Title | Published |
20100209318 | MICROFLUIDIC DEVICES FABRICATED BY DIRECT THICK FILM WRITING AND METHODS THEREOF - The present invention relates to a process for producing a microfluidic device which involves providing a substrate with a surface and writing a first flowable material on the surface of the substrate. The first flowable material is then solidified to form spacer elements, each with a top surface distal from the surface of the substrate, and a second flowable material is written on the surface of the substrate. A cover having a surface is provided and applied to the substrate, with the surface of the cover contacting the top surfaces of the spacer elements. The second flowable material is solidified to form walls, where the walls, the surface of the substrate, and the surface of the cover form flow channels of a microfluidic device. The resulting microfluidic device is also disclosed. | 2010-08-19 |
20100209319 | DEVICE FOR PRODUCING A CRYSTALLIZED SILICON BODY FOR SOLAR CELLS - A device is provided for producing a crystallized silicon body for solar cells. The device includes a reaction vessel, a silicon container arranged within the reaction vessel for containing a raw silicon material, an upper heater arranged above the silicon container for heating the raw silicon material contained in the silicon container, a lower heater arranged below the silicon container for heating the raw silicon material contained in the silicon container, and an insulator unit arranged inside the reaction vessel for surrounding the silicon container, the upper heater and the lower heater. The insulator unit is provided with a side insulator which includes a fixed side insulation member, a plurality of movable side insulation members coupled with the fixed side insulation member and a plurality of side actuators operatively connected to the movable side insulation members for moving the movable side insulation members toward or away from the silicon container. | 2010-08-19 |
20100209320 | SUPPORT RING FOR ACCOMMODATING A PLATE-LIKE ELEMENT IN A VESSEL - A support ring for accommodating a plate-like element in a vessel includes a bracket disposed on a wall of the vessel and configured to support the plate-like element, the bracket having an upper supporting surface inclined downward relative to horizontal. | 2010-08-19 |
20100209327 | STRUCTURED SCR CATALYST FOR THE REDUCTION OF NITROGEN OXIDES IN THE EXHAUST GAS FROM LEAN-BURN ENGINES USING AMMONIA AS REDUCING AGENT - The reductive removal of nitrogen oxides from the exhaust gas from internal combustion engines operated predominantly under lean conditions takes place in a selective catalytic reduction (SCR) of the nitrogen oxides by means of ammonia or a compound which can be decomposed into ammonia as reducing agent. Conventional SCR catalysts typically have a relatively narrow working temperature window, usually 350° C. to 520° C., in which good nitrogen oxide conversions can be achieved with sufficient selectivity. SCR catalyst formulations whose working window is in the temperature range from 150° C. to 350° C. generally not be used at higher temperatures since they oxidize the ammonia required as reducing 18 agent to nitrogen oxides at above 350° C. To cover the entire exhaust gas temperature range typical of vehicles having been operating internal combustion engines extending from 200° C. to 600° C., it has therefore mostly been necessary to use complicated exhaust gas systems containing a plurality of catalysts having different working temperature ranges. Disclosed is a structured SCR catalyst whose working range extends over a significantly broader temperature window and by means of which complicated exhaust gas units can be considerably simplified, with a saving of components. | 2010-08-19 |
20100209328 | METHODS FOR SYNTHESIZING SUBMICRON DOPED SILICON PARTICLES - Methods are described that have the capability of producing submicron/nanoscale particles, in some embodiments dispersible, at high production rates. In some embodiments, the methods result in the production of particles with an average diameter less than about 75 nanometers that are produced at a rate of at least about 35 grams per hour. In other embodiments, the particles are highly uniform. These methods can be used to form particle collections and/or powder coatings. Powder coatings and corresponding methods are described based on the deposition of highly uniform submicron/nanoscale particles. | 2010-08-19 |
20100209331 | ARTIFICIAL GRAPHITE FOR NEGATIVE ELECTRODE OF LITHIUM ION SECONDARY BATTERY, AND METHOD FOR PRODUCTION THEREOF - The artificial graphite for the negative electrode of a lithium ion secondary battery according to the invention has a crystallite size Lc of 60-120 nm in the c-axial direction according to X-ray diffraction, and a crystallite size Lc of 150 nm or greater when subjected to graphitizing at a temperature of 3000° C. in an inert gas atmosphere. | 2010-08-19 |
20100209332 | Nonaqueous Chlorine Dioxide-Generating Compositions and Methods Related Thereto - A method for generating chlorine dioxide is disclosed in which chlorine dioxide generation is activated with a dry polar material. A system for generating chlorine dioxide is also disclosed, as well as compositions useful in the system and method. | 2010-08-19 |
20100209335 | ION CYCLOTRON POWER CONVERTER AND RADIO MICROWAVE GENERATOR - A power source, power converter, and a radio and microwave generator are provided. The power source comprises a cell for the catalysis of atomic hydrogen to release power and to form novel hydrogen species and compositions of matter comprising new forms of hydrogen. The compounds comprise at least one neutral, positive, or negative hydrogen species having a binding energy greater than its corresponding ordinary hydrogen species, or greater than any hydrogen species for which the corresponding ordinary hydrogen species is unstable or is not observed. The energy released by the catalysis of hydrogen produces a plasma in the cell such as a plasma of the catalyst and hydrogen. The power converter and radio and microwave generator comprises a source of magnetic field which is applied to the cell. The electrons and ions of the plasma orbit in a circular path in a plane transverse to the applied magnetic field for sufficient field strength at an ion cyclotron frequency ω | 2010-08-19 |
20100209336 | ULTRATHIN MAGNESIUM NANOBLADES - A nanostructure includes a plurality of metal nanoblades positioned with one edge on a substrate. Each of the plurality of metal nanoblades has a large surface area to mass ratio and a width smaller than a length. A method of storing hydrogen includes coating a plurality of magnesium nanoblades with a hydrogen storage catalyst and storing hydrogen by chemically forming magnesium hydride with the plurality of magnesium nanoblades. | 2010-08-19 |
20100209339 | SILICON-TITANIUM MIXED OXIDE POWDER, DISPERSION THEREOF AND TITANIUM-CONTAINING ZEOLITE PREPARED THEREFROM - Pyrogenic silicon-titanium mixed oxide powder having • a BET surface area of 200 to 400 m | 2010-08-19 |
20100209340 | PYRIDO [2, 3-D] PYRIMIDIN-7-ONE COMPOUNDS AS INHIBITORS OF P13K-ALPHA FOR THE TREATMENT OF CANCER - The invention is directed to Compounds of Formula (I). The invention provides compounds that inhibit, regulate, and/or modulate P13K that are useful in the treatment of hyperproliferative diseases, such as cancer. | 2010-08-19 |
20100209343 | Methods and kits for diagnosis of cancer and prediction of therapeutic value - A method for identifying a patient for cancer therapy can include administering a diagnostic dose of a detectably labeled first binding agent to a patient, the detectably labeled binding agent being capable of binding a molecular target. The method also includes selecting a patient for administration of a therapeutic dose of a second binding agent capable of binding a cellular target, wherein the selected patient exhibits a positive reading for the detectably labeled first binding agent. Furthermore, the method can include administering a therapeutic dose of the second binding agent to the patient. | 2010-08-19 |
20100209344 | Radio-methyl Vorozole and Methods for Making and Using the Same - Radiotracer vorozole compounds for in vivo and in vitro assaying, studying and imaging cytochrome P450 aromatase enzymes in humans, animals, and tissues and methods for making and using the same are provided. [N-radio-methyl] vorozole substantially separated from an N-3 radio-methyl isomer of vorozole is provided. Separation is accomplished through use of chromatography resins providing multiple mechanisms of selectivity. | 2010-08-19 |
20100209345 | Fluorinated Ligands for Targeting Peripheral Benzodiazepine Receptors - The invention provides fluorinated compounds of formula (I): The compounds may be used in diagnosis or treatment of a disorder in a mammal characterised by an abnormal density of peripheral benzodiazepine receptors. | 2010-08-19 |
20100209346 | AMYLOID BETA(1-42) OLIGOMERS, DERIVATIVES THEREOF AND ANTIBODIES THERETO, METHODS OF PREPARATION THEREOF AND USE THEREOF - The invention relates to neuromodulatory oligomers of the amyloid β(1-42) protein, a particular production method, by means of which the oligomer can be obtained in a reproducible manner at high yield, the use of the oligomers and diagnostic and therapeutic agents, for the generation of oligomer-specific antibodies and for the discovery of substances which can interact with the oligomers and in the formation thereof. | 2010-08-19 |
20100209347 | CYCLODEXTRIN COMPOUND MODIFIED WITH FOLIC ACID, PROCESS FOR PRODUCTION THEREOF, DRUG DELIVERY AGENT FOR TARGETING DRUG DELIVERY SYSTEM, PHARMACEUTICAL COMPOSITION, AND IMAGING AGENT - Disclosed is a cyclodextrin compound comprising glucopyranoses constituting cyclodextrin, the glucopyranoses having substituents each having folic acid substituted for two or more primary hydroxy groups at position-6 of the glucopyranoses. | 2010-08-19 |
20100209348 | METHODS FOR DETERMINING LIPOSOME BIOEQUIVALENCE - This invention provides methods for determining liposome bioequivalence between a generic drug product and a reference brand-name product. Specific methods for determining bioequivalence between doxorubicin hydrochloric acid (HCl) liposome injection product (Doxil®) and a generic pegylated liposome doxorubicin product are disclosed herein. | 2010-08-19 |
20100209349 | Phage Therapy Against Pseudomonas Aeruginosa - This invention relates to a bacteriophage MPK6 (deposit number: KCCM 11044P) having a lytic activity to | 2010-08-19 |
20100209350 | Biomarkers for Adipose Tissue Activity - The invention provides compositions and methods for determining a subject's adipose tissue activity. In one embodiment, the composition comprises a solid support comprising probes for measuring a biomarker panel comprising, for example, adiponectin, resistin, PAI-1, optionally leptin and optionally visfatin. The simultaneous use of multiple biomarkers with independent classification power will increase the performance of the biomarker panel in identifying adipose tissue activity, which is associated with various disease states including chronic or systemic inflammation, atherosclerosis and other cardiovascular risks and complications. The invention also provides methods of treating a subject and determining the efficacy of a therapy through assaying the various biomarkers of a biomarker panel disclosed herein. | 2010-08-19 |
20100209352 | SYNTHESIS AND CONJUGATION OF IRON OXIDE NANOPARTICLES TO ANTIBODIES FOR TARGETING SPECIFIC CELLS USING FLUORESCENCE AND MR IMAGING TECHNIQUES - The invention provides for methods for producing water-soluble iron oxide nanoparticles comprising encapsulating the nanoparticles in phospholipids micelles. Also provided are methods for conjugating the inventive nanoparticles via functionalized phospholipids to a target molecule, such as an antibody. The invention further provides methods for using the nanoparticle-antibody conjugate of the invention as a contrast agent to image specific cells or proteins in a subject using fluorescent and magnetic imaging techniques. | 2010-08-19 |
20100209357 | Localized Therapy of Lower Airways Inflammatory Disorders with Proinflammatory Cytokine Inhibitors - The present invention is drawn to methods and compositions for treating inflammatory disorders of the lower airways, comprising administering an effective amount of an agent, which modulates the expression and/or activity of a proinflammatory cytokine or fragment thereof, preferably in a human. The proinflammatory cytokine contemplated by the invention includes IL-1, IL-6, IL-8 and TNF-alpha. The present invention describes a kit comprising a delivery device and a pharmaceutical composition for administration of the agent. The pharmaceutical composition includes at least one proinflammatory cytokine inhibitor, optionally one or more additional active ingredients, and at least one pharmaceutically active carrier. The delivery device further comprises a nebulizer, an inhaler, a powder dispenser, an intrapulmonary aerosolizer and a sub-miniature aerosolizer. | 2010-08-19 |
20100209358 | Method of Making Particles For Use In A Pharmaceutical Composition - The invention relates to a method for making composite active particles for use in a pharmaceutical composition for pulmonary administration, the method comprising a milling step in which particles of active material are milled in the presence of particles of an additive material which is suitable for the promotion of the dispersal of the composite active particles upon actuation of an inhaler. The invention also relates to compositions for inhalation prepared by the method. | 2010-08-19 |
20100209363 | PERSONAL CLEANSING COMPOSITION INCLUDING A STRUCTURED SURFACTANT SYSTEM AND A SUN PROTECTION FACTOR COMPOSITION - A personal cleansing composition includes a structured surfactant system including a blend of surfactants that form spherulite structures in an aqueous medium. The composition also includes water, and at least one sunscreen compound. The personal cleansing composition deposits the at least one sunscreen compound onto skin in a manner whereby the sunscreen compound imparts to the skin a sun protection factor of at least 4 after rinsing the personal cleansing composition. A method for cleansing and providing sun protection factor to skin includes applying to the skin the personal cleansing composition described above and then rinsing it from the skin in a manner whereby a sufficient amount of the at least one sunscreen compound remains deposited onto skin to impart to the skin a sun protection factor of at least 4. | 2010-08-19 |
20100209364 | Emulsified Composition - An emulsified composition comprises (A) petrolatum, (B) lecithin, (C) glycerin, (D) water and (E) a water-soluble polymer, wherein the content of the petrolatum (A) is 10 to 30 wt % relative to 100 wt % of the emulsified composition, and an internal phase of the emulsified composition has an average particle diameter of not more than 800 nm as measured by a dynamic light scattering method based on the dynamic light scattering theory. | 2010-08-19 |
20100209367 | Emulsions Of Silicone Elastomer And Silicone Organic Elastomer Gels - Aqueous emulsions are disclosed of a gel or gel paste containing a silicone elastomer from the reaction an organohydrogensiloxane having at least two SiH containing cyclosiloxane rings in its molecule and a compound having at least two aliphatic unsaturated groups in its molecule. | 2010-08-19 |
20100209368 | METHOD AND PREPARATION FOR TREATING BALDNESS - Various embodiments of the present invention are directed to hair-loss, and include treatments and preparations. Embodiments of the present invention include bactericides, combinations of bactericides and fungicides, combination of bactericides and vasodilators, and combinations of bactericides, fungicides, and vasodilators that are delivered topically to pilosebaceous units within the scalps of persons suffering from hair loss. The treatment kills or controls microbes that disrupt hair growth by changing, inhibiting, or interrupting one or more biological functions of the pilosebaceous units. Certain embodiments of the present invention contain additional active and inactive ingredients, including anti-inflammatory agents, carriers, emulsifiers, antioxidants, and other such substances. | 2010-08-19 |
20100209371 | USE OF RESINS FOR STABILIZING COLORANTS - A process for preparing a cosmetic composition, characterized in that it includes: optionally a pretreatment of an organic ion-exchange resin, the absorption of at least one organic colorant onto the optionally pretreated resin in order to form a resinate, the optional grinding of the resulting resinate and the incorporation of the resinate into a cosmetically acceptable polar medium. It also relates to the composition obtained, to the resinate formed and also to the use of at least one organic ion-exchange resin for stabilizing at least one organic colorant in a cosmetically acceptable polar medium. | 2010-08-19 |
20100209372 | PATCHOULOL ODORANT - The invention relates to the use as perfuming ingredients of 8a-alkyl-perhydro-naphthalenol derivatives, to impart odor notes of the woody-earthy type. | 2010-08-19 |
20100209373 | DITHIOLS AND USE THEREOF FOR STRENGTHENING THE HAIR - The disclosure relates to the use of dithiols for strengthening keratin materials, and to novel dithiols and to cosmetic compositions comprising them. | 2010-08-19 |
20100209374 | Multi-Phase Personal Care Composition Comprising a Stabilizing Perfume Composition - A method of stabilizing a multiphase composition is described. The composition comprises a structured surfactant phase, a benefit phase and a perfume comprising perfume raw materials. The method comprises a step of selecting at least 70% of the perfume raw materials that have a ClogP of greater than 1.8. | 2010-08-19 |
20100209375 | PROCESS FOR TREATING KERATIN FIBERS WITH AT LEAST ONE HETEROCYCLIC DISULFIDE ENTITY IN THE PRESENCE OF AT LEAST ONE REDUCING AGENT, OPTIONALLY HEAT, AND OPTIONALLY AT ALKALINE PH. - The present disclosure relates to a process for treating keratin fibers, comprising: applying to the keratin fibers at least one heterocyclic disulfide entity chosen from those of formula (I), optionally applying to the keratin fibers at least one reducing agent; and/or optionally heating the keratin fibers at a temperature ranging from 50 to 250° C.; optionally at an alkaline pH; it being understood that when the at least one heterocyclic disulfide entity chosen from those of formula (I) is lipoic acid, and at least one reducing agent is applied to the keratin fibers, then the lipoic acid is not present together in the same composition with the at least one reducing agent. The present disclosure also relates to a cosmetic composition, optionally at alkaline pH, comprising, in a cosmetic support: at least one heterocyclic disulfide entity chosen from those of formula (I), and optionally at least one reducing agent; it being understood that when the at least one heterocyclic disulfide entity chosen from those of formula (I) is lipoic acid, and at least one reducing agent is applied to the keratin fibers, then the lipoic acid is not present together in the same composition with the at least one reducing agent. | 2010-08-19 |
20100209376 | Matt Wax - Cosmetic agent for temporarily shaping keratin fibers, which contains, in a cosmetically acceptable carrier, 10 to 85% by weight, based on the entire agent, of at least one wax having a melting point in the range of 40° C. to 90° C. and 1 to 15% by weight of at least one composite powder, which is made up of (A) powder particles of a cured organosiloxane composition having an average particle diameter of 0.1 to 200 μm and (B) amorphous silicon dioxide particles having an average particle diameter of not more than 1 μm, the amorphous silicon dioxide (B) particles being immobilized on the surface of the powder particles of the cured organosiloxane composition (A). The invention also relates to the use of said agent for temporarily shaping hair. | 2010-08-19 |
20100209377 | HAIR STYLING AND CONDITIONING PERSONAL CARE FILMS - The present invention provides personal care compositions in film form having less than about 30 weight percent water-soluble chitosan derivative and greater than about 40 weight percent of a water soluble film forming agent. | 2010-08-19 |
20100209378 | Dimethylcyclohexyl Derivatives as Malodor Neutralizers - Compound of formula (I) | 2010-08-19 |
20100209383 | Use of g-csf for treating ischemia - The present invention relates to uses of granulocyte colony stimulating factor (GCSF) or fragment thereof for the preparation of a pharmaceutical composition for treating organ dysfunction caused by ischemia, whereby the pharmaceutical composition is to be administered to a patient who is subjected to a surgical or interventional procedure in order to improve organ function, to improve organ function, to improve blood flow and/or to induce revascularization. Furthermore, the present invention relates to methods of treating organ dysfunction caused by ischemia comprising administering a therapeutically effective amount of G-CSF or fragment thereof to a patient who is subjected to a surgical or interventional procedure in order to improve organ function, to improve organ function, to improve blood flow and/or to induce revascularization. | 2010-08-19 |
20100209384 | Sustained release formulations comprising very low molecular weight polymers - The present invention relates to a parenteral, sustained and controlled release, semisolid formulation comprising an end-capped oligomer and at least one active substance without any supplementary viscosity reducing agent or excipient. | 2010-08-19 |
20100209391 | NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION - The embodiments provide compounds of the general Formula II, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments also provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition. | 2010-08-19 |
20100209392 | Excipients for use in adeno-associated virus pharmaceutical formulations, and pharmaceutical formulations made therewith - Stable pharmaceutical compositions comprising recombinant adeno-associated virus (AAV) virions are described. The compositions provide protection against loss of recombinant AAV vector genomes and transduceability under conditions such as exposure to cycles of freezing and thawing and storage in glass or polypropylene vials. The compositions comprise recombinant AAV virions in combination with one or more dihydric or polyhydric alcohols, and, optionally, a detergent, such as a sorbitan ester. Also described are methods of using the compositions. | 2010-08-19 |
20100209395 | Solenopsis invicta virus | 2010-08-19 |
20100209396 | Method of Enhancing Proliferation and/or Hematopoietic Differentiation of Stem Cells - The present invention provides methods for inducing differentiation of a stem cell, such as an embryonic stem cell, into a hematopoietic stem cell, by expressing a cdx gene and/or a hox gene. The method is useful for generating expanded populations of hematopoietic stem cells (HSCs) and thus mature blood cell lineages. This is desirable where a mammal has suffered a decrease in hematopoietic or mature blood cells as a consequence of disease, radiation or chemotherapy. | 2010-08-19 |
20100209399 | BRAIN-DERIVED STEM CELLS FOR REPAIR OF MUSCULOSKELETAL SYSTEM IN VERTEBRATE SUBJECTS - The stem cells that can be propagated and maintained for extended periods of time in culture in the absence of a feeder layer, and can be used to repair tissue damage. These cells are derived from fetal tissues and are able to repair different types of damage in musculoskeletal system, with significantly greater efficacy than stem cells derived from adult tissues. These cells are hypoimmunogenic and can be used for allogeneic transplantation to vertebrate hosts having disease and/or damage in musculoskeletal and other tissues. The cells can be administered by direct injection to the site in need of repair or by systemic (e.g., intravenous) administration. The stem cells of the invention are capable of migrating to the sites in need of repair, and of adopting a phenotype most appropriate to the nature of the damage, injury or disease. | 2010-08-19 |
20100209400 | TAK1-Mediated Regulation of Osteogenesis - This invention is directed to methods, nucleic acids and compositions in TAK1-mediated regulation of SMAD activity. Promotion of TAK1 interaction with MH2 domains in SMADs negatively regulates SMAD biological activity. BMP-mediated SMAD activity is subject to TAK1 effects. | 2010-08-19 |
20100209405 | SERICIN EXTRACTED SILKWORM FIBROIN FIBERS - The present invention provides a novel silk-fiber-based matrix having a wire-rope geometry for use in producing a ligament or tendon, particularly an anterior cruciate ligament, ex vivo for implantation into a recipient in need thereof. The invention further provides the novel silk-fiber-based matrix which is seeded with pluripotent cells that proliferate and differentiate on the matrix to form a ligament or tendon ex vivo. Also disclosed is a bioengineered ligament comprising the silk-fiber-based matrix seeded with pluripotent cells that proliferate and differentiate on the matrix to form the ligament or tendon. A method for producing a ligament or tendon ex vivo comprising the novel silk-fiber-based matrix is also disclosed. | 2010-08-19 |
20100209406 | BACILLUS STRAINS AND METHODS FOR REDUCING E. COLI DISEASE AND ENHANCING PERFORMANCE - strains that inhibit pathogenic swine | 2010-08-19 |
20100209408 | Remodeling of Tissues and Organs - The invention provides methods of repairing damage to, or defects in, mammalian tissues or organs. In these methods, a particulate or non-particulate acellular matrix made from a tissue or organ other than the tissue or organ being repaired is placed in or on the organ or tissue that is being repaired. | 2010-08-19 |
20100209409 | METHOD FOR SUPPRESSING IMMUNE SYSTEM RESPONSE TO TRANSPLANTED TISSUE OR CELLS - Methods are provided for suppressing the immune system response in recipients of transplanted organs, tissues or cells. An extracorporeal quantity of blood from the intended transplant recipient is treated to induce monocytes contained in the blood to differentiate and form dendritic cells. The maturation of the dendritic cells is truncated at a stage where the dendritic cells can inactivate T cell clones which would otherwise generate an undesired immune system response. The immature dendritic cells can be directly administered to the transplant recipient, or the dendritic cells can be co-incubated with the bone marrow or stem cell preparation, prior to transplantation, in order to suppress or eliminate anti-recipient donor T cells contaminating the bone marrow or stem cell preparation. The methods can be used to suppress graft versus host disease in recipients of transplanted bone marrow or stem cells, or to suppress rejection of transplanted organs or tissue. | 2010-08-19 |
20100209410 | Combinations Comprising a Fungicidal Strain and an Active Compound - Fungicidal mixtures, comprising
| 2010-08-19 |
20100209413 | SERPINE1 POLYMORPHISMS ARE PREDICTIVE OF RESPONSE TO ACTIVATED PROTEIN C ADMINISTRATION AND RISK OF DEATH - Methods, oligonucleotides arrays etc. for treating inflammatory conditions and of predicting subject outcome based on polymorphisms in SERPINE1 and/or PROC, alone or in combination, wherein the method of treatment includes administering to the subject an anti-inflammatory agent or an anti-coagulant agent, wherein said subject is determined to have an improved response genotype or combination. | 2010-08-19 |
20100209414 | Methods and Compositions Related to Cyclic Peptide Synthesis - Disclosed are compositions and methods for prenylation of polymers such as peptides. | 2010-08-19 |
20100209419 | Method and formulation for treating adverse biological conditions - A method for treatment of adverse biological conditions is provided, wherein a biologically active agent such as a macromolecular biomolecule, e.g., a nucleic acid or a peptidic compound, is administered to a subject in need of such treatment in a formulation containing a transport enhancer having the structure of formula (I) | 2010-08-19 |
20100209420 | METHODS OF TREATING CANCER USING PYRIDOPYRIMIDINONE INHIBITORS OF P13K ALPHA - The present invention provides methods of treating cancer by administering a compound of Formula I, optionally as a pharmaceutically acceptable salt, solvate and/or hydrate thereof, in combination with other cancer treatments. | 2010-08-19 |
20100209425 | Blood-Brain Barrier Targeting Anti-bodies - This invention provides antibodies that bind brain endothelial cell receptors resulting in endocytosis/transcytosis of the receptor and bound ligands. In some embodiments, the ligand comprises the antibody in combination with a pharmaceutically active compound and the antibody directs delivery of the compound across the blood brain barrier (BBB). The invention also provides methods of identifying endothelial cell specific antibodies by panning the library against cultured cell monolayers. The invention further allows for identifying endothelial cell receptors that bind the antibody thereby providing target receptors against which to isolate further cognate ligands and their associated transport systems and by which to identify transcytosis transporters targeted by the antibodies. | 2010-08-19 |
20100209426 | INHIBITORS OF PROGASTRIN-INDUCED REPRESSION OF ICAT FOR TREATING AND/OR PREVENTING COLORECTAL CANCER, ADENOMATOUS POLYPOSIS OR METASTASIS DISPLAYING PROGASTRIN-SECRETING CELLS AND CELLS IN WHICH THE BETA-CATENIN/TCF-MEDIATED TRANSCRIPTIONAL PATHWAY IS CONSTITUTIVELY ACTIVE - The present invention relates to inhibitors of progastrin induced repression of ICAT for treating and/or preventing colorectal cancer, adenomatous polyposis or metastasis displaying progastrin-secreting cells and cells in which the beta-catenin/Tcf-4-mediated transcriptional pathway is constitutively active. | 2010-08-19 |
20100209431 | METAL TRIANGULO COMPOUND AND METHODS OF USING THE SAME - The present invention relates to a metal triangulo compound. Provided is also a method of inducing apoptosis in a cell that comprises administering the metal triangulo compound. Provided is also a method of preventing carcinogenesis in a cell that comprises administering the metal triangulo compound. | 2010-08-19 |
20100209432 | MONOCLONAL ANTIBODIES AGAINST GLYPICAN-3 - The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to Glypican-3 with high affinity. Nucleic acid molecules encoding Glypican-3 antibodies, expression vectors, host cells and methods for expressing the Glypican-3 antibodies are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the Glypican-3 antibodies are also provided. Methods for detecting Glypican-3, as well as methods for treating various Glypican-3-related conditions, including hepatocellular cancer, are disclosed. | 2010-08-19 |
20100209433 | METHODS FOR THE DIAGNOSIS AND FOR THE TREATMENT OF CRITICALLY ILL PATIENTS WITH ENDOTHELIN, ENDOTHELIN AGONISTS AND ADRENOMEDULLIN ANTAGONISTS - The ratio of concentrations of pro-adrenomedullin (pro-ADM)/pro-endothelin (pro-END) immunoreactivity in body fluids of critically ill patients is used for the diagnosis, course control and prognosis, including an assessment of the mortality risk, of severe life threatening diseases. Further, a treatment of critically ill patients having high levels of pro-ADM but insufficient levels of pro-END immunoreactivities with a medicament comprising vasoconstrictive endothelin or its precursors, and/or endothelin agonists or adrenomedullin antagonists is provided. | 2010-08-19 |
20100209434 | ANTIBODY FORMULATION - The present invention provides high concentration liquid formulations of antibodies or fragments thereof that specifically bind to a human interferon alpha polypeptide. | 2010-08-19 |
20100209435 | Human Anti-OPGL Neutralizing Antibodies As Selective OPGL Pathway Inhibitors - Monoclonal antibodies and hybridomas producing them that interact with osteoprotegerin ligand (OPGL) are provided. Methods of treating osteopenic disorders by administering a pharmaceutically effective amount of antibodies to OPGL are also provided. Methods of detecting the amount of OPGL in a sample using antibodies to OPGL are further provided. | 2010-08-19 |
20100209436 | METHOD FOR TREATING DISEASES RELATED TO MITOCHONDRIAL DYSFUNCTION - The present invention relates to means and methods for therapeutic intervention of mitochondrial disorders or diseases, in particular to a method for the treatment, prevention and/or amelioration of a disorder or disease correlated with mitochondrial dysfunction, a mitochondrial disorder or disease or a disorder or disease characterized by an altered OPA1 processing. Thereby, a pharmaceutically active amount of a compound capable of modulating the activity of an oligomeric complex comprising Afg3I1 and/or Afg3I2 or (a) variant(s) thereof is administered to a patient in need of medical intervention. The present invention also relates to the use of an oligomeric complex comprising Afg3I1 and/or Afg3I2 or (a) variant(s) thereof for the preparation of a pharmaceutical composition for the mentioned therapeutic intervention. The present invention further relates to a method of screening for a compound capable of modulating the activity of an oligomeric complex comprising Afg3I1 and/or Afg3I2 or (a) variant(s) thereof comprising the use of OPA1. | 2010-08-19 |
20100209437 | Anti-CD3 Antibody Fromulations - This invention relates to therapeutic, diagnostic and/or prophylactic formulations and dosages of anti-CD3 antibodies, as well as to methods for using such formulations and dosages. | 2010-08-19 |
20100209438 | OVR110 Antibody Compositions and Methods of Use - The invention provides isolated anti-ovarian, pancreatic, lung or breast cancer antigen (Ovr110) antibodies that internalize upon binding to Ovr110 on a mammalian in vivo. The invention also encompasses compositions comprising an anti-Ovr110 antibody and a carrier. These compositions can be provided in an article of manufacture or a kit. Another aspect of the invention is an isolated nucleic acid encoding an anti-Ovr110 antibody, as well as an expression vector comprising the isolated nucleic acid. Also provided are cells that produce the anti-Ovr110 antibodies. The invention encompasses a method of producing the anti-Ovr110 antibodies. Other aspects of the invention are a method of killing an Ovr110-expressing cancer cell, comprising contacting the cancer cell with an anti-Ovr110 antibody and a method of alleviating or treating an Ovr110-expressing cancer in a mammal, comprising administering a therapeutically effective amount of the anti-Ovr110 antibody to the mammal. | 2010-08-19 |
20100209439 | Anti-Prominin-1 Antibody having ADCC Activity or CDC Activity - An objective of the present invention is to provide antibodies that bind to Prominin-1 and have ADCC activity and/or CDC activity, and pharmaceutical compositions containing those antibodies as an active ingredient. | 2010-08-19 |
20100209440 | Targeted Delivery of siRNA - The present invention provides a method of delivering RNA interference molecules to a cell or a cell in a subject, which comprises contacting the cell with a protein-double stranded RNA complex, the complex comprising the double stranded RNA segment containing a double stranded RNA of interest and a protein, the protein comprising (1) a targeting moiety, which will specifically bind to a site on a target cell, and (2) a binding moiety linked thereto, which will bind to the double stranded RNA, wherein the double stranded RNA segment is delivered to a cell and effects RNA interference of the target RNA in the cell. | 2010-08-19 |
20100209443 | Vaccine for the Prevention of Breast Cancer Relapse - The invention features methods to induce and maintain a protective cytotoxic T-lymphocyte response to a peptide of the HER2/neu oncogene, E75, with the effect of inducing and maintaining protective or therapeutic immunity against breast cancer in a patient in clinical remission. The methods comprise administering to the patient an effective amount of a vaccine composition comprising a pharmaceutically acceptable carrier, an adjuvant such as recombinant human GM-CSF, and the E75 peptide at an optimized dose and schedule. The methods further comprise administering an annual or semi-annual booster vaccine dose due to declining E75-specific T cell immunity. The invention also features vaccine compositions for use in the methods. | 2010-08-19 |
20100209444 | MAGE3 Polypeptides - The present invention relates to novel MAGE3 polypeptides, including a fragment of MAGE3 fused to an immunological fusion partner, and compositions thereof. | 2010-08-19 |
20100209445 | MUTANT DOUBLE CYCLIZED RECEPTOR PEPTIDES INHIBITING BETA1-ADRENOCEPTOR ANTIBODIES - The present invention relates to novel β-AR homologous cyclopeptide-mutants comprising only two cysteine residues able to form an intramolecular linkage, to linear peptides that can form these cyclopeptide-mutants and to nucleic acid molecules encoding these cyclopeptide-mutants and linear peptides. Moreover, vectors and recombinant host cells comprising said nucleic acid molecule and a method for producing the disclosed cyclopeptide-mutants are provided. Further provided is a composition comprising the peptides, nucleic acid molecules, vectors or host cells of the invention. The present invention also relates to therapeutic and diagnostic means, methods and uses taking advantage of the peptides of the invention and to means, methods and uses for detecting anti-β-adrenergic receptor antibodies like anti-βradrenergic receptor antibodies. | 2010-08-19 |
20100209446 | Ostertagia Vaccine - The present invention relates to nucleic acid sequences encoding a 30 kD | 2010-08-19 |
20100209455 | THERMAL INACTIVATION OF ROTAVIRUS - Methods of thermally inactivating a rotavirus are provided according to the present invention which include exposing the rotavirus to a temperature in the range of about 50° C.-80° C., inclusive, for an incubation time sufficient to render the rotavirus incapable of replication or infection. The thermally inactivated rotavirus is antigenic and retains a substantially intact rotavirus particle structure. Vaccine compositions and methods of vaccinating a subject against rotavirus are provided which include generation and use of thermally inactivated rotavirus. | 2010-08-19 |
20100209456 | TREATING NEOPLASMS WITH NEUROTOXIN - The present invention provides a method of treating a cancer using a neurotoxin, preferably Botulinum toxin (“BTX”). The application of a neurotoxin around a cancer acts to decrease the contractile forces of the muscles surrounding a neoplasm which normally squeeze cancer cells through efferent channels leaving the cancer vicinity to distant sites. Also, the application of the toxin at sites distant from the cancer enhances cellular and humoral immunologic functions which further contributes to cancer cell death and spread. Following administration of botulinum toxin around and distant to a cancer, it is noticed that local, regional, and distant spread is reduced or eliminated. Immunomodulation with botulinum toxin is also valuable in treating other disease that may or may not be associated with cancers, such as viral-induced growths, viral conditions, fungal disease, chronic wounds, graft versus host disease, autoimmune disease, and HIV. | 2010-08-19 |
20100209457 | PNEUMOCOCCAL SEROTYPE 6D - Disclosed is a new and emerging serotype of | 2010-08-19 |
20100209458 | AMPHIPHILIC MOLECULE, MOLECULAR ASSEMBLY COMPRISING THE AMPHIPHILIC MOLECULE, AND USE OF THE MOLECULAR ASSEMBLY - The present invention provides an amphiphilic molecule having a plurality of zwitterionic functional groups in its hydrophilic moiety and a molecular assembly comprising the amphiphilic molecule as a constituent lipid. According to a preferred embodiment of the present invention, the molecular assembly of the present invention forms a stable vesicular structure under a physiological pH environment to carry a substance of interest in the vesicular structure, and can release the substance of interest to the outside of the vesicular structure when it is deformed under an acidic pH environment. The molecular assembly of the present invention can be used as a carrier for a drug, a probe, a nucleic acid, a protein or the like. | 2010-08-19 |
20100209461 | PURIFIED COMPONENT OF BLUE-GREEN ALGAE AND METHOD OF USE - Disclosed herein are extracts of blue green algae, such as | 2010-08-19 |
20100209462 | Cosmetic compositions Comprising Esters Based on 2-Propylheptanoic Acid - The invention relates to esters of 2-propylheptanoic acid and also to the use of esters of 2-propylheptanoic acid in cosmetic and/or pharmaceutical preparations. The compounds are characterized by the particularly lightweight sensation thereof. | 2010-08-19 |
20100209465 | Shaving Compositions Comprising Dye-Loaded Particles - According to the invention, a non-foaming shaving composition is provided comprising:
| 2010-08-19 |
20100209466 | MEROCYANINE DERIVATIVES - Disclosed is the use of merocyanine derivatives of formula | 2010-08-19 |
20100209471 | MEDICAL DEVICES HAVING POLYMERIC NANOPOROUS COATINGS FOR CONTROLLED THERAPEUTIC AGENT DELIVERY AND A NONPOLYMERIC MACROPOROUS PROTECTIVE LAYER - An implantable or insertable medical device is provided which contains the following: (a) a substrate, (b) a therapeutic agent-containable region disposed over the substrate, (c) a nanoporous polymeric layer disposed over the therapeutic agent-containable region and (d) a macroporous non-polymeric layer disposed over the nanoporous polymeric layer. The nanoporous polymeric layer largely regulates transport of species between the therapeutic agent-containable region and the exterior of the device. The macroporous non-polymeric layer has a larger pore size than the nanoporous polymeric layer and largely serves to isolate the polymeric material from surrounding tissue during in-situ delivery of the therapeutic agents. | 2010-08-19 |
20100209472 | DRUG RELEASING COATINGS FOR MEDICAL DEVICES - The invention relates to a medical device for delivering a therapeutic agent to a tissue. The medical device has a layer overlying the exterior surface of the medical device. The layer contains a therapeutic agent, an antioxidant, and an additive. In certain embodiments, the additive has a hydrophilic part and a drug affinity part, wherein the drug affinity part is at least one of a hydrophobic part, a part that has an affinity to the therapeutic agent by hydrogen bonding, and a part that has an affinity to the therapeutic agent by van der Waals interactions. In some embodiments, the additive is a liquid. In other embodiments, the additive is at least one of a surfactant and a chemical compound, and the chemical compound has one or more hydroxyl, amino, carbonyl, carboxyl, acid, amide or ester groups. | 2010-08-19 |
20100209475 | MEDICAL IMPLANTS HAVING A DRUG DELIVERY COATING - Medical implants having a drug delivery coating, comprising a diffusion matrix made of a collagen matrix, a bioactive material, and a self-arranging transport barrier layer. The bioactive material is contained in the collagen matrix layer and/or the self-arranging transport barrier layer. Methods of preparing the coated implants and methods of modulating the rate of elution of a bioactive material are also provided. | 2010-08-19 |
20100209476 | COATING COMPRISING A TERPOLYMER COMPRISING CAPROLACTONE AND GLYCOLIDE - The present invention provides a coating comprising a reservoir layer comprising a terpolymer comprising caprolactone and glycolide and a primer layer comprising an amorphous polymer on an implantable device and methods of making and using the same. | 2010-08-19 |
20100209477 | SUSTAINED RELEASE DELIVERY OF ONE OR MORE AGENTS - The lacrimal implant delivery systems and methods described herein provide for controlled release of a therapeutic agent for the treatment of disease, including the treatment of glaucoma, ocular hypertension, or elevated intraocular pressure with latanoprost or other anti-glaucoma agents. Treatment of disease, including glaucoma, ocular hypertension, or elevated intraocular pressure with latanoprost or other anti-glaucoma agent in conjunction with penetration enhancer, such as benzalkonium chloride, and/or artificial tears is also provided. Also provided are implants containing a drug core emplacable in a punctum adjacent to an eye of a patient for controlled release of a therapeutic agent such as latanoprost for the treatment of glaucoma, the drug core containing a polymer such as cross-linked silicone, a therapeutic agent, and an excipient, wherein the excipient can increase the rate of release of the agent from the drug core, or can increase the drug loading in the core without loss of desirable homogeneity of the agent within the core, or can improve retention of the agent in the eye or in tear fluid, or can increase corneal penetration of the agent into the eye. | 2010-08-19 |
20100209478 | DRUG DELIVERY THROUGH HYDROGEL PLUGS - An embodiment is a medical prosthesis for blocking or reducing tear flow through a punctum or canaliculus of a human eye and delivering a drug to the eye that comprises a dehydrated covalently crosslinked synthetic hydrophilic polymer hydrogel with dimensions to pass through a puncta lacrimali, with the dehydrated hydrogel absorbing physiological water to swell to at least 1 mm in cross-sectional width and conformably fit a canaliculus, with the hydrogel comprising a therapeutic agent dispersed through the hydrogel for release to an eye, with the hydrogel having a water content of at least about 50% by weight or volume when allowed to fully hydrate in vitro in physiological saline. | 2010-08-19 |
20100209481 | NEW WOUND DRESSING COMPOSITIONS - A wound dressing composition comprising a non-viable cell lysate or releasate derived from a hepatocyte cell or an inflammatory cell such as a macrophage. Also provided are wound dressings comprising such compositions, methods of making such compositions, and the use of such compositions for the treatment of wounds. | 2010-08-19 |
20100209482 | DRESSING SECURING SYSTEM - A dressing securing system for securing a dressing relative to a wound, the dressing securing system comprising a fabric composed of a resilient knitted material. | 2010-08-19 |
20100209483 | TRANSDERMAL DELIVERY OF MEPTAZINOL - A delivery system for the delivery of a salt of meptazinol which increases the bioavailability of meptanizol by an effective amount to provide analgesic relief is disclosed. One embodiment of the delivery system is a transdermal device which increases the skin flux of meptazinol by an effective amount to provide analgesic relief. Also disclosed are methods of providing analgesic relief. | 2010-08-19 |
20100209484 | Transdermal Triptan Delivery System - This invention relates to transdermal system for the systemic administration of an active ingredient such as a triptan selected from the group comprising eletriptan, frovatriptan, sumatriptan, zolmitriptan, naratriptan, rizatriptan and almotriptan uniformly over periods of 12 to 24 hours or more thereby reducing the probability of recurring migraine. The formulation includes active ingredient, adhesive matrix and permeation enhancer. The invention also relates to storage stable formulations and methods for preventing migraine and cessation of an ongoing migraine event. | 2010-08-19 |
20100209489 | Formulations of desvenlafaxine - Controlled release formulations of active compounds with pH-dependent solubility are provided. The formulations comprise solubility modulators which minimize the influence of environment on the solubility of the active compounds. | 2010-08-19 |
20100209490 | IMMUNOLIPOSOME INDUCING APOPTOSIS INTO CELL EXPRESSING DEATH DOMAIN-CONTAINING RECEPTOR - The present invention relates to an immunoliposome preparation having a therapeutic effect on cancer, autoimmune disease, or inflammatory disease. Specifically, the present invention relates to an immunoliposome comprising, as a constituent, an antibody capable of inducing the apoptosis of cells expressing a death domain-containing receptor. | 2010-08-19 |
20100209491 | METHOD FOR ENHANCING SERUM STABILITY AND LOWERING IMMUNE RESPONSE OF SIRNA DOWN-REGULATING GENE EXPRESSION OF HBV OR HCV - A method for enhancing the serum stability and lowering the immunostimulatory property of a small interfering ribonucleic acid (siRNA) which mediates RNA interference (RNAi) against a viral gene expression of hepatitis B virus (HBV) or hepatitis C virus (HCV) is provided. | 2010-08-19 |
20100209492 | Targeted Liposomal Drug Delivery System - A metal targeting complex which associates with a charged liposomal structure is provided. The metal targeting complex provides the targetability of the liposomal construct to the desired receptor sites of a warm-blooded host for therapy or diagnostic use. | 2010-08-19 |
20100209495 | GRANULATES, PROCESS FOR PREPARING THEM AND PHARMACEUTICAL PRODUCTS CONTAINING THEM - A granulate for use in a pharmaceutical composition and a pharmaceutical composition manufacture using the granulate, where the granule comprises an active pharmaceutical ingredient (API) having a poor water solubility (i.e., less than about 1 mg/mL) which is intimately associated with at least one pharmaceutically acceptable hydrophilic polymer. The granule optionally contains one or more pharmaceutically acceptable excipients, such as disintegrants, wetting agents, diluents, binders, lubricants, glidants, coloring agents and flavoring agents. The invention also relates to a process for preparing the pharmaceutical granulate and pharmaceutical compositions containing the granulate. | 2010-08-19 |
20100209496 | LIQUID AND SEMI-SOLID PHARMACEUTICAL FORMULATIONS FOR ORAL ADMINISTRATION OF A SUBSTITUTED AMIDE - 3-[(3aR,4R,5S,7aS)-5-{(1R)-1-[3,5-bis(Trifluoromethyl)phenyl]ethoxy}-4-(4-fluorophenyl)-octahydro-2H-isoindol-2-yl]cyclopent-2-en-1-one (Compound I) has surprisingly improved solubility, bioavailability and stability in an ampiphilic vehicle that can include propylene glycol, a propylene glycol sparing agent, an antioxidant, or a mixture thereof. In one embodiment of the present invention is a solution comprising the active or a pharmaceutically acceptable salt or solvate thereof, and an amphiphilic agent, said amphiphilic agent being a fatty acid ester of glycerol, propylene glycol or sorbitol. | 2010-08-19 |
20100209499 | Solid Oral Dosage Form Containing an Enhancer - The invention relates to a solid oral dosage form comprising a pharmaceutically active ingredient in combination with an enhancer which enhances the bioavailability and/or the absorption of the active ingredient. Accordingly, a solid oral dosage form comprises a drug and an enhancer wherein the enhancer is a medium chain fatty acid ester, ether or salt or a derivative of a medium chain fatty acid, which is, preferably, solid at room temperature and which has a carbon chain length of from 6 to 20 carbon atoms. Preferably, the solid oral dosage form is controlled release dosage form such as a delayed release dosage form. | 2010-08-19 |
20100209500 | CONTROLLED RELEASE BUDESONIDE MINITABLETS - Embodiments of a controlled release minitablet comprise an extended release core and an optional pH dependent delayed release coating thereon, wherein the extended release core comprises budesonide, a carrier, an extended release polymer, and an acid. The budesonide may be embedded in the extended release polymer to facilitate extended release of the budesonide upon administration. | 2010-08-19 |
20100209505 | Controlled release pharmaceutical formulations of nitazoxanide - Solid dosage formulations of nitazoxanide or a nitazoxanide analogue are provided that comprise a controlled release portion and an immediate release portion. The pharmaceutical composition is typically in the form of a bilayer solid oral dosage form comprising (a) a first layer comprising a first quantity of nitazoxanide or analogue thereof in a controlled release formulation; and (b) a second layer comprising a second quantity of nitazoxanide or analogue thereof in an immediate release formulation. Method of using the formulations in the treatment of hepatitis C are also provided. | 2010-08-19 |
20100209506 | PHARMACEUTICAL COMPOSITION, PHARMACEUTICAL DOSAGE FORM, PROCESS FOR THEIR PREPARATION, METHODS FOR TREATING AND USES THEREOF - The present invention relates to pharmaceutical compositions of linagliptin, pharmaceutical dosage forms, their preparation, their use and methods for treating metabolic disorders. | 2010-08-19 |
20100209507 | METHODS OF DIAGNOSING AND TREATING SMALL INTESTINAL BACTERIAL OVERGROWTH (SIBO) AND SIBO-RELATED CONDITIONS - Disclosed is a method of treating small intestinal bacterial overgrowth (SIBO) or a SIBO-caused condition in a human subject. SIBO-caused conditions include irritable bowel syndrome, fibromyalgia, chronic pelvic pain syndrome, chronic fatigue syndrome, depression, impaired mentation, impaired memory, halitosis, tinnitus, sugar craving, autism, attention deficit/hyperactivity disorder, drug sensitivity, an autoimmune disease, and Crohn's disease. Also disclosed are a method of screening for the abnormally likely presence of SIBO in a human subject and a method of detecting SIBO in a human subject. A method of determining the relative severity of SIBO or a SIBO-caused condition in a human subject, in whom small intestinal bacterial overgrowth (SIBO) has been detected, is also disclosed. | 2010-08-19 |
20100209508 | Substituted Phenylphosphates as Mutual Prodrugs of Steroids and -Agonists for the Treatment of Title Pulmonary Inflammation and Bronchoconstriction - A mutual prodrug of a corticosteroid and a substituted phenylphosphate (β-agonist derivative) for formulation for delivery by aerosolization to inhibit pulmonary inflammation and bronchoconstriction is described. The mutual prodrug is preferably formulated in a small volume solution (10-500 μL) dissolved in a quarter normal saline having pH between 5.0 and 7.0 for the treatment of respiratory tract inflammation and bronchoconstriction by an aerosol having mass median average diameter predominantly between 1 to 5μ, produced by nebulization or by dry powder inhaler. | 2010-08-19 |
20100209513 | PHARMACEUTICAL COMPOSITION CONTAINING MICRONIZED PARTICLES OF NAPHTHOQUINONE-BASED COMPOUND - Provided is a pharmaceutical composition having excellent in vivo absorption properties by increasing solubility and absorption rate of a sparingly-soluble naphthoquinone-based compound via incorporation of micronized particles of a certain naphthoquinone-based compound. | 2010-08-19 |
20100209514 | Method of treating pain by administering 24 hour oral oploid formulations exhibiting rapid rate of initial rise of plasma drug level - Patients are treated with 24-hour oral sustained release opioid formulations which, upon administration, provide an initially rapid opioid absorption such that the minimum effective analgesic concentration of the opioid is more quickly achieved. These sustained release opioid formulations include an effective amount of at least one retardant material to cause said opioid analgesic to be released at a such a rate as to provide an analgesic effect after oral administration to a human patient for at least about 24 hours, and are characterized by providing an absorption half-life from 1 to about 8 hours. A method of titrating a human patient utilizing these sustained release opioid formulations is also disclosed. | 2010-08-19 |
20100209515 | ELECTRICITY-GENERATING PARTICULATES AND THE USE THEREOF - The invention features a galvanic particulate including a first conductive material and a second conductive material, wherein both the first conductive material and the second conductive material are exposed on the surface of the particulate, wherein the particle size of the particulate is from about 10 nanometers to about 100 micrometers, wherein the second conductive material comprises from about 0.01 percent to about 10 percent, by weight, of the total weight of the particulate, and wherein the difference of the standard potentials of the first conductive material and the second conductive material is at least about 0.2 V. | 2010-08-19 |